Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, Wilhelm M, Wilhelm C, Pezzutto A, Zijlstra JM, Neste EVD, Lugtenburg PJ, Doorduijn JK, Gelder MV, van Imhoff GW, Zettl F, Braulke F, Nickelsen M, Glass B, Rosenwald A, Gaulard P, Loeffler M, Pfreundschuh M, Schmitz N, Trümper L; ACT-2 study investigators. Wulf GG, et al. Among authors: van imhoff gw. Leukemia. 2021 Jan;35(1):143-155. doi: 10.1038/s41375-020-0838-5. Epub 2020 May 7. Leukemia. 2021. PMID: 32382083 Clinical Trial.
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ. Chamuleau MED, et al. Among authors: van imhoff gw. Haematologica. 2020 Dec 1;105(12):2805-2812. doi: 10.3324/haematol.2019.238162. Haematologica. 2020. PMID: 33256379 Free PMC article. Clinical Trial.
Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, van Putten WLJ, Luten M, Oudejans J, van Imhoff GW. Kluin-Nelemans HC, et al. Among authors: van marwijk kooy m, van putten wlj, van imhoff gw. Ann Oncol. 2011 Jul;22(7):1595-1600. doi: 10.1093/annonc/mdq635. Epub 2011 Jan 6. Ann Oncol. 2011. PMID: 21212158 Free article. Clinical Trial.
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW. Verdonck LF, et al. Among authors: van imhoff gw. Blood. 2007 Apr 1;109(7):2759-66. doi: 10.1182/blood-2006-07-035709. Blood. 2007. PMID: 17132720 Free article. Clinical Trial.
Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC. Doorduijn JK, et al. Among authors: van der holt b, van den bent mj, van imhoff gw. Hematol Oncol. 2017 Dec;35(4):497-503. doi: 10.1002/hon.2342. Epub 2016 Aug 17. Hematol Oncol. 2017. PMID: 27530779 Clinical Trial.
Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.
Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group. Lugtenburg PJ, et al. Among authors: van imhoff gw. Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10. Br J Haematol. 2019. PMID: 31290569 Free article. Clinical Trial.
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P. Doorduijn JK, et al. Among authors: van oers mh, van agthoven m, van der hem kg, van der holt b, van imhoff gw. J Clin Oncol. 2003 Aug 15;21(16):3041-50. doi: 10.1200/JCO.2003.01.076. J Clin Oncol. 2003. PMID: 12915593 Clinical Trial.
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ, Huijgens PC. Vellenga E, et al. Among authors: van putten wl, van oers mh, van t veer mb, van imhoff gw. Blood. 2008 Jan 15;111(2):537-43. doi: 10.1182/blood-2007-08-108415. Epub 2007 Oct 30. Blood. 2008. PMID: 17971487 Free article. Clinical Trial.
Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer.
Rigter LS, Schaapveld M, Janus CPM, Krol ADG, van der Maazen RWM, Roesink J, Zijlstra JM, van Imhoff GW, Poortmans PMP, Beijert M, Lugtenburg PJ, Visser O, Snaebjornsson P, van Eggermond AM, Aleman BMP, van Leeuwen FE, van Leerdam ME. Rigter LS, et al. Among authors: van imhoff gw. Cancer Med. 2019 Jan;8(1):190-199. doi: 10.1002/cam4.1922. Epub 2018 Dec 27. Cancer Med. 2019. PMID: 30592184 Free PMC article.
128 results